Doctors Urge Medicare to Deny Coverage for Alzheimer’s Drug With Unproven Efficacy and Safety

If Medicare decides to cover up to 80% of Aduhelm's cost, "many beneficiaries would pay thousands of dollars of out-of-pocket costs for a drug with substantial risks and without proven clinical benefit."